Publication:
Synthesis of hydrazine containing piperazine or benzimidazole derivatives and their potential as a-amylase inhibitors by molecular docking, inhibition kinetics and in vitro cytotoxicity activity studies

Simple item page
dc.contributor.authorERDEM, SAFİYE
dc.contributor.authorsCakmak, Ummuhan; Oz-Tuncay, Fulya; Basoglu-Ozdemir, Serap; Ayazoglu-Demir, Elif; Demir, Ilke; Colak, Ahmet; Celik-Uzuner, Selcen; Erdem, Safiye Sag; Yildirim, Nuri
dc.date.accessioned2022-03-12T22:55:57Z
dc.date.available2022-03-12T22:55:57Z
dc.date.issued2021
dc.description.abstractThe alpha-amylase is the main product of pancreas and is necessarily involved in the hydrolysis of carbohydrates into glucose so that it has been known to be a pioneer target for type 2 Diabetes mellitus (DM). Type 2 DM has no certain cure and the global increase in the cases of DM requires effective and extensive number of drug candidates. Drug discovery studies using organic biochemistry approaches are of important to describe novel compounds. This study aimed to reveal inhibitory potential of 13 novel compounds containing piperazine or benzimidazole moieties on alpha-amylase. The novel compounds were synthesized, structurally corroborated by various spectral analysis (FTIR, UV-Vis, H-1 NMR and C-13 NMR) and screened for anti alpha-amylase activity. Among the synthesized derivatives, compound 14 was found to be the most potent inhibitor of alpha-amylase having IC50 64.8 +/- 1.8 mu M. Inhibition types and K-i values of the most effective molecules (14 and 10a with different moieties) were further investigated. Molecular docking studies were conducted to correlate the outcome of in vitro biochemical kinetic assays and therefore rationalize the binding interactions. In vitro cytotoxicity studies on pancreatic cancer (AR42J) cells were then performed for compound14, and the compound was found to be more effective compared to the positive control, acarbose. Prediction of in silico ADME properties of all tested molecules were determined.
dc.identifier.doi10.1007/s00044-021-02785-8
dc.identifier.eissn1554-8120
dc.identifier.issn1054-2523
dc.identifier.urihttps://hdl.handle.net/11424/236862
dc.identifier.wosWOS:000687006800001
dc.language.isoeng
dc.publisherSPRINGER BIRKHAUSER
dc.relation.ispartofMEDICINAL CHEMISTRY RESEARCH
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPiperazine
dc.subjectBenzimidazole
dc.subjectalpha-amylase inhibition
dc.subjectMolecular docking
dc.subjectCell culture
dc.subjectMICROWAVE-ASSISTED SYNTHESIS
dc.subjectPANCREATIC ALPHA-AMYLASE
dc.subjectCELL-CYCLE ARREST
dc.subjectCANCER CELLS
dc.subjectANTIMICROBIAL ACTIVITY
dc.subjectBIOLOGICAL EVALUATION
dc.subjectDENSITY FUNCTIONALS
dc.subjectHYBRID MOLECULES
dc.subjectDRUG DESIGN
dc.subjectAPOPTOSIS
dc.titleSynthesis of hydrazine containing piperazine or benzimidazole derivatives and their potential as a-amylase inhibitors by molecular docking, inhibition kinetics and in vitro cytotoxicity activity studies
dc.typearticle
dspace.entity.typePublication
local.avesis.id508efdcb-087d-453f-a21f-9e51b6358ed5
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages19
oaire.citation.endPage1904
oaire.citation.issue10
oaire.citation.startPage1886
oaire.citation.titleMEDICINAL CHEMISTRY RESEARCH
oaire.citation.volume30
relation.isAuthorOfPublication99f2f09c-7e48-402f-9bb9-ccdd73c27ec2
relation.isAuthorOfPublication.latestForDiscovery99f2f09c-7e48-402f-9bb9-ccdd73c27ec2

Files

Collections

Research Outputs